Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001127602-22-008780
Filing Date
2022-03-09
Accepted
2022-03-09 16:24:11
Documents
1
Period of Report
2022-03-07

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT form4.html 4  
1 PRIMARY DOCUMENT form4.xml 4 3287
  Complete submission text file 0001127602-22-008780.txt   4664
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Issuer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 2190 PARKWAY LAKE DR BIRMINGHAM AL 35244
Business Address
Babu Yarlagadda S (Reporting) CIK: 0001452635 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-23186 | Film No.: 22725665